- Home
- SGU vs AQST Comparison
SGU vs AQST Comparison
Compare SGU & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGU
- AQST
- Stock Information
- Founded
- SGU 1995
- AQST 2004
- Country
- SGU United States
- AQST United States
- Employees
- SGU N/A
- AQST N/A
- Industry
- SGU Other Specialty Stores
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- SGU Consumer Discretionary
- AQST Health Care
- Exchange
- SGU Nasdaq
- AQST Nasdaq
- Market Cap
- SGU 390.2M
- AQST 390.4M
- IPO Year
- SGU 1995
- AQST 2018
- Fundamental
- Price
- SGU $11.98
- AQST $5.84
- Analyst Decision
- SGU
- AQST Strong Buy
- Analyst Count
- SGU 0
- AQST 7
- Target Price
- SGU N/A
- AQST $10.29
- AVG Volume (30 Days)
- SGU 37.0K
- AQST 3.6M
- Earning Date
- SGU 08-06-2025
- AQST 11-03-2025
- Dividend Yield
- SGU 6.24%
- AQST N/A
- EPS Growth
- SGU 33.71
- AQST N/A
- EPS
- SGU 1.66
- AQST N/A
- Revenue
- SGU $1,777,057,000.00
- AQST $44,132,000.00
- Revenue This Year
- SGU N/A
- AQST N/A
- Revenue Next Year
- SGU N/A
- AQST $51.50
- P/E Ratio
- SGU $7.14
- AQST N/A
- Revenue Growth
- SGU N/A
- AQST N/A
- 52 Week Low
- SGU $10.84
- AQST $2.12
- 52 Week High
- SGU $13.75
- AQST $6.43
- Technical
- Relative Strength Index (RSI)
- SGU 62.64
- AQST 62.29
- Support Level
- SGU $11.61
- AQST $5.47
- Resistance Level
- SGU $11.98
- AQST $5.93
- Average True Range (ATR)
- SGU 0.18
- AQST 0.36
- MACD
- SGU 0.04
- AQST 0.01
- Stochastic Oscillator
- SGU 96.72
- AQST 62.43
About SGU Star Group L.P.
Star Group LP is a company engaged in providing home heating products and services to residential and commercial customers. The company offers heating oil and air conditioning equipment, as well as home security and plumbing services. The company also sells diesel fuel, gasoline, and home heating oil. Geographically, the company operates in U.S.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.